Levodopa/Carbidopa Teva (Levodopa, Carbidopa Monohydrate)

Levodopa serves as a precursor to dopamine and crosses the blood‑brain barrier where it is converted into dopamine, replenishing the depleted neurotransmitter in Parkinsonian patients. Carbidopa blocks peripheral decarboxylation of levodopa, increasing the amount that reaches the brain and reducing peripheral side effects like nausea.

The dosage of Levodopa/Carbidopa Teva is individualized and determined by the prescribing clinician based on the patient’s disease severity, response, and tolerability. The prescriber will adjust the dose and frequency to achieve optimal symptom control while minimizing adverse effects.

Safety data for Levodopa/Carbidopa in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for Parkinson’s disease, directly restoring dopamine levels. Compared with dopamine agonists, it often provides stronger motor improvement but may cause more motor complications over time. MAO‑B inhibitors and COMT inhibitors are used as adjuncts to extend levodopa’s effect, while anticholinergics target specific tremor symptoms.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Levodopa/Carbidopa Teva is taken orally, usually as a tablet. It can be taken with or without food, although a high‑protein meal may interfere with absorption. The prescribing physician will advise the appropriate dosing schedule, which often involves multiple daily doses to maintain steady symptom control.

Serious risks include the development of dyskinesias (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension that can lead to fainting, and rare but life‑threatening conditions such as neuroleptic malignant syndrome. Patients should be monitored regularly for these adverse events, especially when doses are escalated.

Levodopa/Carbidopa Teva is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, or any excipients. It should be avoided in individuals taking non‑selective MAO inhibitors, those with narrow‑angle glaucoma, or patients with severe cardiovascular disease where rapid blood‑pressure changes could be hazardous.